This protocol is designed to assess the need for seizure prophylaxis in the perioperative
period for patients undergoing neurosurgical procedure (gross-total resection, sub-total
resection or biopsy) for suspected diagnosis of new, recurrent or transformed glioma (WHO
grade I-IV) and brain metastasis. This will be determined by observing the impact of
Lacosamide (LCM), Levetiracetam (LEV), or no anti-epileptic drug (AED) on whether visits to
the emergency department (ED) or hospital re-admissions occur within 30 days after procedure.
A secondary endpoint will evaluate the safety and tolerability of LCM and LEV. Exploratory
endpoints will evaluate admission duration for the procedure, number of post-operative
provider communications (telephone, email, and additional clinic encounters, etc.), and
patient risk factors associated with post-operative seizure.